U.S., Jan. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07343115) titled 'Familial Systemic Scleroderma' on Jan. 06.
Brief Summary: Studying familial forms of systemic scleroderma offers several advantages:
1. To better understand the pathophysiology of a complex autoimmune disease based on "extreme" cases (familial forms);
2. To identify potential molecular markers predictive of disease progression;
3. To identify potential pathophysiological targets for developing new therapies, particularly relevant in severe and refractory forms of the disease.
Study Start Date: Sept. 02, 2025
Study Type: OBSERVATIONAL
Condition:
Systemic Scleroderma
Recruitment Status: RECRUITING
Sponsor: University Hospital...